A share price of Homology Medicines Inc [FIXX] is currently trading at $0.86, up 1.30%. An important factor to consider is whether the stock is rising or falling in short-term value. The FIXX shares have gain 19.74% over the last week, with a monthly amount glided 45.38%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 3, January 2024, Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency. In a post published today on Yahoo Finance, Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement.
From an analyst’s perspective:
Homology Medicines Inc [NASDAQ: FIXX] stock has seen the most recent analyst activity on July 28, 2023, when Robert W. Baird downgraded its rating to a Neutral and also revised its price target to $1.50 from $9. Previously, BTIG Research reaffirmed its Neutral rating on February 22, 2022, and dropped its price target to $29. On February 22, 2022, downgrade downgraded it’s rating to Sector Perform. Oppenheimer downgraded its rating to a Perform. Stifel initiated its recommendation with a Hold and recommended $14 as its price target on March 02, 2021. In a note dated August 11, 2020, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $37 to $30.
Homology Medicines Inc experienced fluctuations in its stock price throughout the past year between $0.46 and $1.76. Currently, Wall Street analysts expect the stock to reach $2.7 within the next 12 months. Homology Medicines Inc [NASDAQ: FIXX] shares were valued at $0.86 at the most recent close of the market. An investor can expect a potential return of 213.95% based on the average FIXX price forecast.
Analyzing the FIXX fundamentals
Trailing Twelve Months sales for Homology Medicines Inc [NASDAQ:FIXX] were 1.96M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8359 points at the first support level, and at 0.8096 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8785, and for the 2nd resistance point, it is at 0.8948.
Homology Medicines Inc [FIXX] reported earnings per share of -$0.57 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.42/share, meaning a difference of -$0.15 and a surprise factor of -35.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.61 per share as compared to estimates of -$0.47 per share, a difference of -$0.14 representing a surprise of -29.80%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Homology Medicines Inc [NASDAQ:FIXX] is 4.22. On the other hand, the Quick Ratio is 4.22, and the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 25.57, the price to book ratio is 0.57.
Transactions by insiders
Recent insider trading involved TZIANABOS ARTHUR, Director, that happened on Jan 09 when 13037.0 shares were sold., Alloway Paul completed a deal on Jan 03 to sell 7280.0 shares. Meanwhile, Michaud Charles Jr sold 1708.0 shares on Jan 03.
